The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6)

E. David Crawford presents the potential mechanisms for differences in cardiovascular risk with different forms of ADT including; metabolic status, exacerbation of underlying cardiovascular disease (CVD) and preclinical data.  In addition, a discussion on the need for the risk of CVD to be assessed prior to the use of ADT. 


Additional related content: 

• Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer
• PRONOUNCE Trial
• Considerations in the use of Androgen Deprivation Therapy for the Treatment of Men with Advanced Prostate Cancer